55 studies found for:    Empagliflozin
Show Display Options
Rank Status Study
1 Completed Does the Intake of Food Influence the Uptake of Empagliflozin (BI 10773) ? Does the Amount of Empagliflozin (BI 10773), That is Taken up Into the Body After Intake of 10 mg and 25 mg Tablets, Increase Proportional With the Dose ?
Condition: Healthy
Intervention: Drug: Empagliflozin
2 Completed Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773 25 mg;   Drug: Warfarin 25 mg;   Drug: Warfarin
3 Completed Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Condition: Healthy
Interventions: Drug: BI 10773/linagliptin;   Drug: BI 10773/linagliptin SID;   Drug: BI 10773/linagliptin FDC
4 Completed Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773;   Drug: Gemfibrozil
5 Completed Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
Condition: Healthy
Interventions: Drug: Empagliflozin/Metformin XR, FDC;   Drug: Empagliflozin/Metformin XR FDC;   Drug: 25 mg Empafliglozin/1000 mg Metformin XR, FDC;   Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
6 Not yet recruiting Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
Condition: Healthy
Interventions: Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 10 mg Empagliflozin/1000 mg Metformin XR;   Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR;   Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR
7 Completed Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Placebo;   Drug: Sitagliptin 100mg
8 Recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo
9 Recruiting Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
10 Completed Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773;   Drug: Ramipril
11 Completed A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: empagliflozin (low dose qd);   Drug: Empagliflozin (high dose qd);   Drug: empagliflozin (high dose bid);   Drug: empagliflozin (low dose bid)
12 Completed Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo (low dose);   Drug: Placebo (mid dose);   Drug: Placebo (high dose);   Drug: BI 10773
13 Active, not recruiting Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin medium placebo;   Drug: Empagliflozin low placebo;   Drug: Empagliflozin high placebo;   Drug: Empagliflozin medium;   Drug: Empagliflozin low;   Drug: Empagliflozin high
14 Completed Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Metformin;   Drug: Empagliflozin/Metformin
15 Completed Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: BI10773
16 Completed Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 high dose;   Drug: high dose FDC placebo;   Drug: linagliptin;   Drug: low dose FDC placebo;   Drug: BI 10773 linagliptin FDC;   Drug: high dose BI 10773 placebo;   Drug: BI 10773 low dose;   Drug: linagliptin placebo;   Drug: low dose BI 10773 placebo
17 Completed Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: C: BI 10773 / metformin tablet;   Drug: B: BI 10773 tablet and metformin tablet;   Drug: A: BI 10773 / metformin tablet
18 Not yet recruiting Bioavailability of Empagliflozin/Metformin Fixed Dose Combination(FDC) in Healthy Chinese Volunteers
Condition: Healthy
Interventions: Drug: 5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin;   Drug: 850 mg metformin;   Drug: 5 mg empagliflozin;   Drug: 12.5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin/500 mg metformin FDC;   Drug: 5 mg empagliflozin/500 mg metformin FDC;   Drug: 500 mg metformin
19 Completed Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI10773 high dose;   Drug: BI 10773;   Drug: BI 10773 open label;   Drug: Placebo identical to BI10773 low dose;   Drug: Placebo identical to Sitagliptin 100mg;   Drug: BI10773;   Drug: Sitagliptin
20 Completed Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI 10773 high dose;   Drug: Placebo identical to BI 10773 low dose;   Drug: BI 10773

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years